JNJ Stock: Buy or Sell? Price Target & Forecast

Q: Is JNJ a buy right now?

Johnson & Johnson's current read is a value_income_defensive setup with 72 confidence over a 6-12 months horizon. Valuation: fairly_valued_with_premium_for_quality. See the full bull and bear case above, or run a live analysis for the exact entry, target and stop.

Q: Is JNJ overvalued?

fairly_valued_with_premium_for_quality (valuation score 68/100). JNJ commands premium multiple (P/E 30.8x) due to fortress balance sheet, brand moat, and dividend stability. ForwardPE 24.2x < trailing 30.8x suggests modest compression priced in. P/S 6.9x, P/B 6.1x, EV/EBITDA 17.4x all high in absolute terms but defensible for a AAA-rated compounder with 28.5% net margin and 14.9% 5Y EPS growth. Upside limited if growth disappoints; downside protected by dividend + low beta.

Q: What are the risks of buying JNJ?

P/S 6.9x, P/B 6.1x, EV/EBITDA 17.4x all elevated vs pharma peers; PEG missing suggests limited growth repricing room. Trailing P/E 30.8x pricey for 5.6% revenue growth. Quick ratio 0.69 + currentRatio 1.03 tight; interestCoverage, debt/equity data missing raise liquidity concerns. Patent cliffs, regulatory risk, M&A integration residue loom.

Analyses / JNJ

JNJ Johnson & Johnson As of Jul 29, 2026

$266.73

Stable dividend play with moderate valuation headwinds; strong margins, steady FCF, low beta support defensive positioning.

Setup: value_income_defensive Confidence: 72 Horizon: 6-12 months Risk: medium Category: Large-Cap Pharma / Healthcare

🔒 Trade Plan — entry · target · stop

Entry Zone

$•••–•••

Target

$•••

Stop Loss

$•••

Risk / Reward

•.• : 1

Unlock the exact levels — free →

A free account reveals JNJ's entry zone, price target & stop loss. Full 1-week to 1-year price forecasts are included with Pro.

The Thesis

▲ Bull Case

JNJ trades on unmatched brand moat, 28.5% net margin, 2% dividend yield, ultra-low 0.22 beta, 14.9% 5Y EPS growth. Insider buys outnumber sells (122 vs 137), signaling steady confidence. ForwardPE 24.2x < trailing 30.8x suggests moderation. Pharma sector inflows + dividend demand underpin floor.

▼ Bear Case

P/S 6.9x, P/B 6.1x, EV/EBITDA 17.4x all elevated vs pharma peers; PEG missing suggests limited growth repricing room. Trailing P/E 30.8x pricey for 5.6% revenue growth. Quick ratio 0.69 + currentRatio 1.03 tight; interestCoverage, debt/equity data missing raise liquidity concerns. Patent cliffs, regulatory risk, M&A integration residue loom.

Valuation

fairly_valued_with_premium_for_quality — score 68/100

JNJ commands premium multiple (P/E 30.8x) due to fortress balance sheet, brand moat, and dividend stability. ForwardPE 24.2x < trailing 30.8x suggests modest compression priced in. P/S 6.9x, P/B 6.1x, EV/EBITDA 17.4x all high in absolute terms but defensible for a AAA-rated compounder with 28.5% net margin and 14.9% 5Y EPS growth. Upside limited if growth disappoints; downside protected by dividend + low beta.

Technical Levels

Support · $250.00 (200D MA / key support zone) · $265.00 (Recent breakout, hold above) · $240.00 (52W avg, structural floor)

Resistance · $274.90 (52W high, overbought threshold) · $285.00 (3m target, next upside cap) · $300.00 (Psychological, 1Y bull target)

RSI: Data unavailable

Financial Health

Score 74/100. Strong operating margins (34.6%) and consistent EPS growth support debt servicing. Quick ratio 0.69 lower than ideal; suggests reliance on ongoing collections and credit lines. AAA credit rating from major agencies (external knowledge) confirms investment-grade health. Missing debt-to-equity and interest coverage detail limits comprehensive audit. Likely manageable given scale and free cashflow.

Catalysts

Q3/Q4 earnings (EPS guidance raise)	Next 60 days	Upside 5–8% if beats and raises; reaffirms 6–8% growth thesis.
FDA approvals (pipeline readout)	Next 6–12 months	Major catalyst if oncology or immunology asset approved; could unlock $2–5 per share upside.
Dividend increase announcement	Typically Q4	Annual raise likely (history of <2% CAGR raises); modest positive for income investors.
M&A activity or portfolio restructuring	Unpredictable	Tuck-in acquisition or spin-off could unlock value; material 10–15% swing possible.
Patent cliff (blockbuster loss)	2025–2027	Downside risk if major meds face generic erosion sooner than expected; could pressure EPS 5–10%.

Risk Flags

PEG ratio missing; unable to cross-check growth-adjusted valuation fairness.

Balance sheet, cashflow statements unavailable; debt/equity, ROIC, FCF data absent.

RSI, sentiment, fundamentals detail missing; relying on price action and insider flow only.

Quick ratio 0.69 signals potential short-term liquidity constraint; monitor quarterly trends.

Trailing P/E 30.8x elevated; forward 24.2x better, but room for multiple compression if growth disappoints.

See JNJ's full trade plan — free

Create a free account to unlock the exact entry, target, and stop — plus run live analysis on any of 5,000+ tickers. No card required.

Unlock JNJ free →

More Analyses

NVDA

AAPL

TSLA

MSFT

AMZN

GOOGL

JNJ FAQ

Is JNJ a buy right now?